Patents by Inventor Colin Stott

Colin Stott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220062197
    Abstract: The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and/or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.
    Type: Application
    Filed: September 10, 2021
    Publication date: March 3, 2022
    Inventors: Colin STOTT, Nick Jones, Benjamin Whalley, Gary Stephens, Claire Williams
  • Publication number: 20220062211
    Abstract: The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of cannabis such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.
    Type: Application
    Filed: September 9, 2021
    Publication date: March 3, 2022
    Inventors: Colin STOTT, Nicholas JONES, Robin WILLIAMS, Benjamin WHALLEY
  • Patent number: 11147783
    Abstract: The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of cannabis such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: October 19, 2021
    Assignee: GW Research Limited
    Inventors: Colin Stott, Nicholas Jones, Robin Williams, Benjamin Whalley
  • Patent number: 11147776
    Abstract: The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and/or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: October 19, 2021
    Assignee: GW Research Limited
    Inventors: Colin Stott, Nick Jones, Benjamin Whalley, Gary Stephens, Claire Williams
  • Patent number: 11065227
    Abstract: The present invention relates to the use of a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in the treatment of multiple myeloma. The combination of THC and CBD appears to be particularly effective in reducing cell viability and cell migration in this disease. Preferably the THC and CBD are used is in the form of a highly purified extract of cannabis such that the cannabinoids are present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the THC and CBD may be a synthetically produced cannabinoid.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: July 20, 2021
    Assignee: GW Research Limited
    Inventors: Colin Stott, Massimo Nabissi
  • Patent number: 10758514
    Abstract: The present invention relates to the use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer. Preferably the phytocannabinoids used are either tetrahydrocannabinol (THC) and/or cannabidiol (CBD). Preferably the type of cancer to be treated is glioma.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: September 1, 2020
    Assignee: GW Pharma Limited
    Inventors: Wai Liu, Katherine Scott, Angus Dalgleish, Marnie Duncan, Colin Stott
  • Publication number: 20200206152
    Abstract: The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and/or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.
    Type: Application
    Filed: October 3, 2019
    Publication date: July 2, 2020
    Applicant: GW Research Limited
    Inventors: Colin Stott, Nick Jones, Benjamin Whalley, Gary Stephens, Claire Williams
  • Publication number: 20190175547
    Abstract: The present invention relates to the use of a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in the treatment of multiple myeloma. The combination of THC and CBD appears to be particularly effective in reducing cell viability and cell migration in this disease. Preferably the THC and CBD are used is in the form of a highly purified extract of cannabis such that the cannabinoids are present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the THC and CBD may be a synthetically produced cannabinoid.
    Type: Application
    Filed: July 31, 2017
    Publication date: June 13, 2019
    Inventors: Colin STOTT, Massimo NABISSI
  • Patent number: 10258580
    Abstract: The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: April 16, 2019
    Assignee: GW Pharma Limited
    Inventors: Teresa Iuvone, Vincenzo Di Marzo, Geoffrey Guy, Stephen Wright, Colin Stott
  • Publication number: 20190099398
    Abstract: The present invention relates to the use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer. Preferably the phytocannabinoids used are either tetrahydrocannabinol (THC) and/or cannabidiol (CBD). Preferably the type of cancer to be treated is glioma.
    Type: Application
    Filed: May 2, 2018
    Publication date: April 4, 2019
    Applicant: GW Pharma Limited
    Inventors: Wai LIU, Katherine SCOTT, Angus DALGLEISH, Marnie Duncan, Colin Stott
  • Patent number: 10226433
    Abstract: The present invention relates to the use of cannabinoids in the treatment of degenerative skeletal muscle disease. In particular the degenerative skeletal muscle disease is Duchenne muscular dystrophy (DMD). Preferably the cannabinoids are one or more of: Cannabidiol (CBD); Cannabidivarin (CBDV); and Tetrahydrocannabivarin (THCV).
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: March 12, 2019
    Assignee: GW Research Limited
    Inventors: Vincenzo Di Marzo, Colin Stott, Keith Foster, Fabio Iannotti
  • Patent number: 10098867
    Abstract: The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: October 16, 2018
    Assignee: GW Research Limited
    Inventors: Farideh Afshin Javid, Marnie Duncan, Colin Stott
  • Publication number: 20180263952
    Abstract: The present invention relates to the use of one or more cannabinoids in the treatment of an inflammatory skin disease. Preferably the one or more cannabinoids are taken from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV). The inflammatory skin disease may be caused by one or more of the following: microbial infection-induced dermatitis; solar dermatitis; atopic dermatitis; and allergic contact dermatitis.
    Type: Application
    Filed: September 29, 2016
    Publication date: September 20, 2018
    Applicant: GW Pharma Limited
    Inventors: Tamás Bíró, Colin Stott, Vincenzo Di Marzo
  • Publication number: 20180228751
    Abstract: The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of cannabis such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 16, 2018
    Inventors: Colin STOTT, Nicholas JONES, Robin WILLIAMS, Benjamin WHALLEY
  • Patent number: 10039724
    Abstract: The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (NAFLD), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis. The present invention relates to the use of 7-hydroxy-cannabidiol (7-OH-CBD) in the treatment of non-alcoholic fatty liver disease (NAFLD). Treatment of NAFLD involves lowering the triglyceride levels in a patient's blood stream.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: August 7, 2018
    Assignee: GW Research Limited
    Inventors: Colin Stott, Marnie Duncan, Vincenzo Di Marzo, Cristoforo Silvestri, Andrea Martella
  • Patent number: 9962341
    Abstract: The present invention relates to an active pharmaceutical ingredient (API) which comprises or consists essentially of cannabidiol (CBD) and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer. These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer. Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: May 8, 2018
    Assignee: GW Pharma Limited
    Inventors: Colin Stott, Marnie Duncan, Thomas Hill
  • Patent number: 9895342
    Abstract: The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: February 20, 2018
    Assignee: GW Pharma Limited
    Inventors: Sabatino Maione, Francesco Rossi, Geoffrey Guy, Colin Stott, Tetsuro Kikuchi
  • Publication number: 20180042975
    Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
    Type: Application
    Filed: June 12, 2017
    Publication date: February 15, 2018
    Applicants: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Daniela Parolaro, Paola Massi, Angelo Antonio Izzo, Francesca Borrelli, Gabriella Aviello, Vincenzo Di Marzo, Luciano De Petrocellis, Aniello Schiano Moriello, Alessia Ligresti, Ruth Alexandra Ross, Lesley Ann Ford, Sharon Anavi-Goffer, Manuel Guzman, Guillermo Velasco, Mar Lorente, Sofia Torres, Tetsuro Kikuchi, Geoffrey Guy, Colin Stott, Stephen Wright, Alan Sutton, David Potter, Etienne De Meijer
  • Publication number: 20170304217
    Abstract: The present invention relates to the use of cannabinoids in the treatment of degenerative skeletal muscle disease. In particular the degenerative skeletal muscle disease is Duchenne muscular dystrophy (DMD). Preferably the cannabinoids are one or more of: Cannabidiol (CBD); Cannabidivarin (CBDV); and Tetrahydrocannabivarin (THCV).
    Type: Application
    Filed: October 14, 2015
    Publication date: October 26, 2017
    Applicant: GW Pharma Limited
    Inventors: Vincenzo Di Marzo, Colin Stott, Keith Foster, Fabio Iannotti
  • Publication number: 20170209390
    Abstract: The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and/or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.
    Type: Application
    Filed: June 29, 2015
    Publication date: July 27, 2017
    Inventors: Colin Stott, Nick Jones, Benjamin Whalley, Gary Stephens, Claire Williams